Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $28
Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $37 to $28.
Last updated: 2026-11-19 11:13:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Alumis Inc. (ALMS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.41, with a market capitalization of $628.33M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.35 to $31.35. This page covers its latest market performance, valuation, price trends and company information.
$628.33M | |
$4.41 | |
$4.41 | |
$4.41 | |
$4.39 | |
179.00 | |
2.88M | |
-- | |
$31.35 | |
$4.35 | |
-- | |
2026-09-30 |
Alumis Inc. (ALMS) is trading at $4.41 in pre-market trading as of 2026-11-19 10:51:00, up 0.23% ($0.01) from the previous close of $4.40
Pre-market trading shows how investors are pricing ALMS before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Alumis Inc. (ALMS) moved from $6.40 to $4.41, representing a decline of 31.17% ($2.00).
The stock traded between $4.35 and $6.72 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.75 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.2%
ALMS is currently trading at $4.41, placing it 0.2% of the way from its 52-week low of $4.35 to its 52-week high of $31.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 253 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Alumis Inc. and ALMS stock.
Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $37 to $28.
Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $25 to $18.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Alumis (NASDAQ:ALMS) with a Buy and lowers the price target from $15 to $9.
Eligible investors can buy real shares of Alumis Inc. (ALMS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ALMS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ALMS shares and USD.
ALMS Shares to USD
1.00 ALMS shares = 4.405 USD
Calculations are estimates based on the latest available price and are for reference only.